Powerful Biology.  Novel Medicines.  Transformative Impact.


We presented preliminary findings from our ongoing Phase 1a/1b dose escalation study of NGM120 in patients with advanced solid tumors at the ESMO Virtual Congress 2021.

Powerful Biology.  Novel Medicines.  Transformative Impact.

Latest News

We unveiled our fourth oncology candidate, NGM831, an ILT3 antagonist antibody

NGM831, NGM707 and NGM438 comprise our comprehensive myeloid reprogramming strategy.

Powerful Biology.  Novel Medicines.  Transformative Impact.


NGM707, now in Phase 1/2 study, is a novel dual antagonist inhibiting ILT2 and ILT4

ILT2 and ILT4 may serve as checkpoints that enable tumors to evade immune detection.

Powerful Biology.  Novel Medicines.  Transformative Impact.


NGM438 is a novel antagonist antibody inhibiting LAIR1

LAIR1 may form a stromal checkpoint that impedes anti-tumor immunity.

Powerful Biology.  Novel Medicines.  Transformative Impact.


To translate complex powerful biology with urgency and rigor to deliver life-changing medicines

View our pipeline of novel investigational medicines spanning multiple therapeutic areas.

Powerful Biology.  Novel Medicines.  Transformative Impact.


NGM621's potential: reducing disease progression in geographic atrophy (GA)

GA is a progressive retinal degenerative disease
impacting over 5 million people worldwide.

Powerful Biology.  Novel Medicines.  Transformative Impact.


We love working together and challenging each other to pursue great science that will deliver a big impact for patients.

Curious, creative and driven to make a difference?
Consider NGM to advance your career!


We aspire to operate one of the most productive R&D engines in the biopharma industry.

Our broad, diverse pipeline of novel, first-in-class medicines spans multiple therapeutic areas and diseases. Every program focuses on a large market indication with high unmet needs and a common goal: delivering outsized impact for patients.


We have built our company around core scientific values that frame our approach to drug discovery and development.

Our Core Values

Latest News

View all press releases

NGM621 for Geographic Atrophy (GA)

NGM621, our anti-complement C3 antibody, is currently in Phase 2 study (CATALINA) as a treatment to potentially reduce disease progression in patients with GA and with the potential for every eight week dosing.

Learn More

Working Here

Our People Are Our Platform.

What makes NGM tick? Really smart team members who love working together to pursue great science and share a common drive to deliver a huge impact for patients. We have no hierarchies. We collaborate intensively, embrace risk freely and always swing for the fence.

Join Us